Document is current

Article History

Received: 29 September 2025

Accepted: 16 February 2026

First Online: 12 March 2026

Declarations

:

: This budget impact model used previously collected or published data; thus, ethical review was not required. The study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments.

: Yanqing Xu, Janet Nguyen, and Kaylee Miu are employees of AbbVie, Inc. and hold stock/options. Chia-Wei Lin and Melissa Montez are employees of Genentech, Inc., and hold stock/options of Roche Holding. Xinglei Chai and Xin Chen are employees of Analysis Group, Inc., which has received consulting fees from Genentech, Inc. and AbbVie, Inc., for the conduct of this study. Thomas W. LeBlanc is a Scholar in Clinical Research of Blood Cancer United, and has received honoraria for consulting/advisory boards from AbbVie, Agios/Servier, Apellis, Astellas, BMS/Celgene, Daiichi-Sankyo, Genentech, Geron, Gilead, GSK, Lilly, Menarini-Stemline, Novartis, Novo Nordisk, Pfizer, Syndax, and Taiho; speaking related honoraria from AbbVie, Agios/Servier, Astellas, BMS/Celgene, Daiichi-Sankyo, Geron, GSK, Incyte, Menarini-Stemline and Rigel; equity interest in Dosentrx and ThymeCare (stock options in privately-held companies); royalties from UpToDate; and research funding from AbbVie, AstraZeneca, BMS, Deverra Therapeutics/Coeptis, GSK, Jazz Pharmaceuticals, and Novartis.